Angelobcbrito

[Erman Akkus @Erman_Akkus]

From operating room to pathology report: Delphi consensus on pathological assessment of peritoneal cytology and biopsies in staging laparoscopy for gastric cancer

https://t.co/4tDS0CwpZ6

[NonsparseOncologist @5_utr]

❗️ Bayesian Thinking

Very high yield talk w/slides

Must-read stuff for graduate and medical students, biomedical researchers, clinicians

🫡 @f2harrell

https://t.co/2nl695T4dq

[Hong Jae Chon @hongjaechon]

💡 #GPC3 CAR T cells in #HCC: how much armouring is enough, and what comes next? @NatRevClinOncol
📊 C-CAR031, a GPC3 CAR T armoured with a dominant-negative TGFb receptor II, gave ORR 44.4% in 36 heavily pretreated patients, but median DOR was only 4.4 months.
📊 Resistance ran through two routes: GPC3 loss and rising TGFb signalling that overwhelmed the armour.
👉 Antigen escape is the more tractable one. Dual or tandem-antigen CARs could help, but only if the second target is functionally relevant.
👉 GPC3-PET could track this without repeat biopsies.
👉 And why only T cells? The liver is rich in NK, MAIT and myeloid cells, so CAR NK, CAR MAIT and CAR macrophages deserve comparison.
DOI: https://t.co/FCJbD5WofZ
@ILCAnews @EASLnews @myESMO #LiverX #CART

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Review article: Ovarian metastases from CRC
▪️24 retrospective studies, 2,705 patients
▪️Ovarian mets showed lower response to chemo, less shrinkage, and frequent discordant growth vs extraovarian disease.
👉The ovary may act as a relative chemotherapy-resistant sanctuary site. In cases where ovarian mets show discordant progression despite response at other mets, surgical resection may be worth considering.
🔗https://t.co/bu7v8rN8dk
@JAMAOnc @OncoAlert

[Dr. Cathy Eng @CathyEngMD]

Should we rechallenge with #immunotherapy after developing a prior side effect? Nice slide from @Sam_Cytryn. The earlier the prior #SAE the increased likelihood of repeat adverse event. @OLNGreatDebates #cancer #CancerResearch @YJanjigianMD

[Erman Akkus @Erman_Akkus]

Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies

https://t.co/nsJwKUvOzX

[Arndt Vogel @ArndtVogel]

🔥great news🔥
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
https://t.co/u4Mr4ijEcu
👉expanding options for patients with FGFR2 fusions!
@myESMO @ASCO @ILCAnews @EASLedu

[Erman Akkus @Erman_Akkus]

🚀Upper GI oral abstracts of #ESMO26 👇

✅Gastric/esophageal
✅Pancreatic
✅Hepatobiliary
✅NET/NEC

#cancer #oncology #MedX #GI #pancreatic #biliary #cholangiocarcinoma #liver #hepatocellular #gastric #esophageal #neuroendocrine @OncoAlert

[Atanas G. Atanasov @_atanas_]

An experimental blood test detected 87% of early-stage pancreatic ductal cancers in an international study.

[Timothée Olivier, MD @Timothee_MD]

"Statistics in Oncology in Practice", fom my talk available at https://t.co/nTsm6LeKo2

A change in sample size should always be transparently explained.

If not, there is a risk of what we call "p-hacking", "data-dredging"

See here with an example with the PANOVA trial👇

[Arndt Vogel @ArndtVogel]

🔥off the press🔥
Precision oncology in GI-cancer: Mechanisms of action, indications and ongoing strategies to overcome primary and secondary resistance
Seminars in Cancer Biology
👉PO is fascinating , but complex
👉No magic bullet, much to consider: vertical & sequential pathway inhibitions, persister & resistance mechanisms, rechallenge...
Our thoughts👇
https://t.co/T2AA1lAlqw

[Timothée Olivier, MD @Timothee_MD]

"Statistics in Oncology in Practice", my new talk is available at https://t.co/gbrSccFxE2

Here is an excerpt: understanding the principles of Kaplan-Meier is fundamental, a practical example with LUNAR @Alfdoc2 !

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 TROP2 | GC/GEJ

👥 N=272
📈 TROP2-high (≥75%): 62%
🔬 Largely independent of CLDN18.2, PD-L1 & MMR
⚠️ No prognostic impact
🎯 ~31% of metastatic TROP2-high tumors lacked other key biomarkers

💡 Broad potential therapeutic target.

🔗 https://t.co/PujKfP7BwS

@OncoAlert

[Erman Akkus @Erman_Akkus]

Liquid biopsy for early detection of pancreatic ductal adenocarcinoma

https://t.co/5hNY5nXHmt

[Hong Jae Chon @hongjaechon]

💡 Does prolonging preop chemo (6mo) beat 4mo+#adjuvant in R/BR #PDAC? @eClinicalMed
👉 No EFS benefit with longer course (HR 0.98, p=0.90)
👉 Longer course improved CA19-9 response (97% vs 84%, p=0.02), pCR (5% vs 0%, p=0.05), N0 resection (45% vs 27%, p=0.01)
DOI: https://t.co/ASWr5q1oxJ
@EASLnews @ILCAnews @myESMO #CASSANDRA #Neoadjuvant

[Hong Jae Chon @hongjaechon]

🔥 No head-to-head trials compare first-line #HCC combo therapies.
Researchers reconstructed patient data from KM curves (IPDfromKM) to rank them indirectly.
New analysis in World J Gastrointest Pharmacol Ther (8 phase III RCTs) 👇
👉 vs #sorafenib: camrelizumab + rivoceranib had the best HR (0.61); cabozantinib+atezolizumab showed no benefit
👉 vs #lenvatinib: nivolumab+ipilimumab and pembrolizumab+lenvatinib showed modest, similar gains
🧐 Comparator choice (sorafenib vs lenvatinib) shapes the results — a descriptive, not causal, ranking.
DOI: https://t.co/moi4oV3mLO
@ILCAnews @myESMO @EASLnews
#LiverX #Immunotherapy #IndirectComparison

[Hong Jae Chon @hongjaechon]

💡 Early hepatic #decompensation (eCHD) predicts worse survival in #HCC on #ICI therapy #SeminarsInOncology @casadei_gardini
👉 #eCHD hit 31% of cohorts, nearly halving median OS (AB: 5.5 vs 16.2mo, STRIDE: 5.2 vs 13.6mo)
👉 Still significant after adjusting for baseline liver function
DOI: https://t.co/y3vqBUAwOv

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 MATTERHORN | Phase III | Resectable GC/GEJ

👥 948 pts
💊 Periop durvalumab + FLOT vs FLOT
🎯 pCR 19% vs 7%
⏳ 2-y EFS 67.4% vs 58.5% | HR .71
📈 3-y OS 69% vs 62% | OS HR .78, P=.021

💡 New perioperative SoC.

🔗 https://t.co/RLH9v0Pyux

@OncoAlert

[Erman Akkus @Erman_Akkus]

Futibatinib after Non-Covalent FGFR Inhibitors in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Clinical Activity and Resistance Patterns - European Journal of Cancer https://t.co/lBgKf7AOd6

[Erman Akkus @Erman_Akkus]

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study https://t.co/dQ33H7EZg5